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Abstract
Aripiprazole is a D2-like receptor (D2R) partial agonist with a favourable clinical profile. Previous
investigations indicated that acute and short-term administration of aripiprazole had effects on PKA activity,
GSK3β-dependent pathways, GABAA receptors, NMDA receptor and CREB1 in the brain. Since
antipsychotics are used chronically in clinics, the present study investigated the long-term effects of chronic
oral aripiprazole treatment on these cellular signalling pathways, in comparison with haloperidol (a D2R
antagonist) and bifeprunox (a potent D2R partial agonist). We found that the Akt-GSK3β pathway was
activated by aripiprazole and bifeprunox in the prefrontal cortex; NMDA NR2A levels were reduced by
aripiprazole and haloperidol. In the nucleus accumbens, all three drugs increased Akt-GSK3β signalling; in
addition, both aripiprazole and haloperidol, but not bifeprunox, increased the expression of Dvl-3, β-catenin
and GABAA receptors, NMDA receptor subunits, as well as CREB1 phosphorylation levels. The results
suggest that chronic oral administration of aripiprazole affects schizophrenia-related cellular signalling
pathways and markers (including Akt-GSK3β signalling, Dvl-GSK3β-β-catenin signalling, GABAA receptor,
NMDA receptor and CREB1) in a brain-region-dependent manner; the selective effects of aripiprazole on
these signalling pathways might be associated with its unique clinical effects.
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Chronic administration of 
aripiprazole activates GSK3β-
dependent signalling pathways, 
and up-regulates GABAA receptor 
expression and CREB1 activity  
in rats
Bo Pan1,2, Xu-Feng Huang2 & Chao Deng1,2
Aripiprazole is a D2-like receptor (D2R) partial agonist with a favourable clinical profile. Previous 
investigations indicated that acute and short-term administration of aripiprazole had effects on PKA 
activity, GSK3β-dependent pathways, GABAA receptors, NMDA receptor and CREB1 in the brain. 
Since antipsychotics are used chronically in clinics, the present study investigated the long-term 
effects of chronic oral aripiprazole treatment on these cellular signalling pathways, in comparison with 
haloperidol (a D2R antagonist) and bifeprunox (a potent D2R partial agonist). We found that the Akt-
GSK3β pathway was activated by aripiprazole and bifeprunox in the prefrontal cortex; NMDA NR2A 
levels were reduced by aripiprazole and haloperidol. In the nucleus accumbens, all three drugs increased 
Akt-GSK3β signalling; in addition, both aripiprazole and haloperidol, but not bifeprunox, increased 
the expression of Dvl-3, β-catenin and GABAA receptors, NMDA receptor subunits, as well as CREB1 
phosphorylation levels. The results suggest that chronic oral administration of aripiprazole affects 
schizophrenia-related cellular signalling pathways and markers (including Akt-GSK3β signalling,  
Dvl-GSK3β-β-catenin signalling, GABAA receptor, NMDA receptor and CREB1) in a brain-region-
dependent manner; the selective effects of aripiprazole on these signalling pathways might be 
associated with its unique clinical effects.
Aripiprazole is a unique antipsychotic drug with a pharmacological profile different from other available antip-
sychotics, and this difference has been attributed to its partial agonism for the dopamine D2 receptor (D2R). A 
large body of evidence has shown that most antipsychotic drugs (including aripiprazole and haloperidol) have 
a potent affinity at the D2Rs1, regulating the D2R downstream protein kinase B (Akt)-glycogen synthase kinase 
3 beta (GSK3β ) and protein kinase A (PKA) signalling pathways2. In addition, these two signalling pathways 
are also linked to several other pathways or substrates, such as the dishevelled(Dvl)-GSK3β -β -catenin pathway, 
γ -aminobutyric acid (GABA)A receptor and cAMP-responsive element-binding protein 1 (CREB1)3–5.
GSK3β -dependent signalling pathways are involved in the pathophysiology of schizophrenia and the actions 
of antipsychotics4. First, GSK3β is a major downstream regulator of D2-like receptors that is targeted by most 
antipsychotics6. It has been reported that chronic haloperidol treatment phosphorylates GSK3β , and inhibits its 
activity, which is associated with increased phosphorylation levels of Akt in the frontal cortex7. Second, antip-
sychotic administration can also influence the Dvl-GSK3β -β -catenin signalling pathway. Several studies have 
reported that various antipsychotics (including clozapine, haloperidol, risperidone, olanzapine and aripiprazole) 
were able to increase phosphorylation of GSK3β and expression of Dvl and β -catenin in the frontal cortex and 
striatum8–12.
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The G protein-dependent PKA pathway is another downstream signalling pathway of D2-like receptors. PKA 
signalling has been shown to be related to the pathophysiology of schizophrenia by a post-mortem study13. An 
in vivo study has indicated that acute administration of haloperidol and olanzapine increased the expression 
of PKA catalytic subunits in the rat caudate putamen (CPu)14; PKA signalling has also been elevated by acute 
administration of haloperidol in the striatum15; and furthermore, the activity of the PKA pathway and expression 
of PKA regulatory subunits in the striatum were elevated after a 3-week administration of haloperidol in various 
brain regions, but decreased by clozapine administration16. A recent study has shown that 1-week administration 
of aripiprazole increased PKA phosphorylation in the nucleus accumbens (NAc), but reduced it in the CPu, while 
haloperidol decreased it in both the NAc and CPu17.
The GABAA receptor has been reported to be involved in the pathophysiology of schizophrenia18. Increased 
binding density of GABAA receptors have been found in the prefrontal cortex (PFC)19,20, cingulate cortex21, 
superior temporal gyrus22 and hippocampus23 of schizophrenic subjects. Antipsychotic administration has been 
shown to have various effects on GABAA receptors. It has been reported that 1-week treatment with both halo-
peridol and olanzapine increased the binding density of [3H]-Muscimol labelled GABAA receptors24 in the PFC. 
Zink and colleagues25 have found that haloperidol administration for 6 months increased the binding density of 
GABAA receptors in the CPu and core of the NAc, but reduced it in the PFC, anterior cingulate and infralimbic 
cortex; and 6-month clozapine administration reduced the bindings of GABAA receptors in the anterior cingulate 
and infralimbic cortex. Recent data suggested that expression of GABAA receptors in the rat NAc was elevated by 
1-week aripiprazole administration, probably by activation of the PKA pathway17.
CREB1 is also a downstream substrate of the PKA pathway26. Novel variants in the CREB1 gene have been 
identified in schizophrenic subjects, and a relationship between CREB1 and the positive symptoms of schizophre-
nia has been proposed27. Previous in vivo and in vitro studies have shown that haloperidol increased phospho-
rylation levels of CREB128–30. Additionally, amisulpride, clozapine and olanzapine also elevated phosphorylation 
levels of CREB1 in vitro31–33. Furthermore, a 3-week injection of aripiprazole changed the phosphorylation levels 
of CREB1 in the PFC and striatum of rats, probably through NMDA receptors34. A recent short-term study has 
reported that aripiprazole increased the gene and protein expression of CREB1, probably through the PKA path-
way, in the NAc of rats17.
N-methyl-D-aspartate receptors (NMDARs) have been shown to be associated with schizophrenia and can 
be modulated by antipsychotics5. Blockade of NMDARs exacerbates symptoms in schizophrenia individuals35 
or induces abnormal behaviours that resemble the symptoms and cognitive deficits of schizophrenia in healthy 
subjects36,37. Previous studies showed that antipsychotic drug administration had various effects on NMDARs, 
depending on the classes of antipsychotics, treatment methods (e.g. dosages, modes of drug delivery and time 
frames) and brain regions38–41. Therefore, the NMDAR subunits were also examined in the present long-term 
study.
Recent in vivo studies showed that acute and short-term administration of aripiprazole – a potent D2R par-
tial agonist – displayed different effects that cannot be achieved by haloperidol (a typical antipsychotic and a 
potent D2R antagonist) and bifeprunox (a potent D2R partial agonist), providing preliminary in vivo evidence 
that neither D2R partial agonism nor D2R antagonism could be solely explain the pharmacological mechanism 
and unique clinical effects of aripiprazole17,42. It should also be noted that in clinics, antipsychotics require a long 
treatment period to reach maximum therapeutic effect, and thus are often used chronically43. All previous chronic 
studies administered antipsychotics by various methods (e.g. mixing in drinking water, daily injection), rather 
than the oral administration that mimics the clinical situation. The chronic effects of aripiprazole by such oral 
administration are not clear. Therefore, the present study investigated the effects of 10-week oral administration 
of aripiprazole by examining PKA signalling, Akt-GSK3β and Dvl-GSK3β -β -catenin pathways, GABAA receptors 
and CREB1 activity, in comparison with haloperidol and bifeprunox.
Results
The effect of antipsychotics on Akt and GSK3β activity. PFC. It has been shown that the expression 
of total Akt and total GSK3β was significantly affected by 10-week antipsychotic drug administration in the PFC 
(Akt, F3, 20 = 5.201, p = 0.004; GSK3β , F3, 20 = 3.083, p = 0.026); however, the levels of p-Akt and p-GSK3β were not 
significantly affected (p-Akt, F3, 20 = 1.554, p = 0.232; p-GSK3β , F3, 20 = 1.208, p = 0.332). The ratio of p-Akt/Akt 
(F3, 20 = 4.523, p = 0.007) and p-GSK3β /GSK3β (F3, 20 = 4.112, p = 0.010) was also significantly affected by antip-
sychotic drug administration. Post-hoc testing demonstrated that chronic administration of both aripiprazole 
and bifeprunox reduced expression of Akt (aripiprazole, − 14.2%, p = 0.014; bifeprunox, − 13.6%, p = 0.008) in 
the PFC (Fig. 1A,D). Additionally, administration of aripiprazole significantly suppressed GSK3β expression (by 
25.0%; p = 0.043) compared with controls (Fig. 2A,D). The levels of p-Akt and p-GSK3β were not significantly 
affected. In addition, aripiprazole and bifeprunox administration significantly increased the ratio of p-Akt/Akt 
(aripiprazole, p = 0.021; bifeprunox, p = 0.005) (Fig. 1A). The ratio of p-GSK3β /GSK3β was also increased by 
administration of aripiprazole (p = 0.012) and bifeprunox (p = 0.019) (Fig. 2A).
CPu. Chronic antipsychotic drug administration had no significant effects on the levels of Akt, p-Akt (Fig. 1B,D), 
GSK3β and p-GSK3β (Fig. 2B,D) in the CPu compared with controls (all p > 0.05).
NAc. Drug treatment was able to significantly change the levels of p-Akt (F3, 20 = 4.315, p = 0.009), p-GSK3β 
(F3, 20 = 9.798, p < 0.001), as well as the ratio of p-Akt/Akt (F3, 20 = 5.268, p = 0.004) and p-GSK3β /GSK3β (F3, 20 = 7.024, 
p = 0.001) in the NAc. Compared with the control group, both bifeprunox and haloperidol administration 
significantly elevated the levels of p-Akt in the NAc (bifeprunox, + 38.1%, p = 0.010; haloperidol, + 40.8%, 
p = 0.006); aripiprazole also tended to increase the levels of p-Akt (+ 25.3%, p = 0.072) (Fig. 1C,D). All three 
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Figure 1. Effects of three antipsychotics on Akt activity. The effects of aripiprazole (ARI), bifeprunox (BIF) 
and haloperidol (HAL) on Akt activity were measured in the prefrontal cortex (A), caudate putamen (B) and 
nucleus accumbens (C). The representative bands of Western blot are shown in (D). Akt was quantified at 
60 kDa; p-Akt was quantified at 60 kDa. The data were normalised by taking the average value of the control 
group as 100% and expressed as mean ± S.E.M. (* p ≤ 0.05, * * p < 0.01 vs the control).
Figure 2. Effects of three antipsychotics on GSK3β activity. The effects of aripiprazole (ARI), bifeprunox 
(BIF) and haloperidol (HAL) on GSK3β activity were measured in the prefrontal cortex (A), caudate putamen 
(B) and nucleus accumbens (C). The representative bands of Western blot are shown in (D). GSK3β was 
quantified at 46 kDa; p-GSK3β was quantified at 46 kDa. The data were normalised by taking the average value 
of the control group as 100% and expressed as mean ± S.E.M. (* p ≤ 0.05, * * p < 0.01 vs the control).
www.nature.com/scientificreports/
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drugs increased the ratio of p-Akt/Akt (aripiprazole, p = 0.044; bifeprunox, p = 0.007; haloperidol, p = 0.002) 
(Fig. 1C). Furthermore, administration of all three was able to elevate the levels of p-GSK3β (aripiprazole, 
+ 69.3%, p < 0.001; bifeprunox, + 33.2%, p = 0.026; haloperidol, + 38.4%, p = 0.010) (Fig. 2C,D) and significantly 
increased the ratio of p-GSK3β /GSK3β (aripiprazole, p = 0.001; bifeprunox, p = 0.048; haloperidol, p = 0.005) 
(Fig. 2C).
The effect of antipsychotics on Dvl-3 and β-catenin expression. Chronic antipsychotic adminis-
tration had significant effects on the expression of Dvl-3 (F3, 20 = 4.629, p = 0.007) and β -catenin (F3, 20 = 15.704, 
p < 0.001) in the NAc. Post-hoc tests indicated that the protein levels of Dvl-3 were significantly elevated by 
administration of both aripiprazole (+ 40.8%, p = 0.011) and haloperidol (+ 33.7%, p = 0.031) in the NAc; they 
also significantly increased the expression of β -catenin (aripiprazole, + 30.3%, p = 0.008; haloperidol, + 49.6%, 
p < 0.001) (Fig. 3C,D). Additionally, the ratio of p-GSK3β /GSK3β was positively correlated with the expression of 
β -catenin (r = 0.297, p = 0.039) (Fig. 4A). On the other hand, no significant effect was observed in the other two 
brain areas (Fig. 3A,B,D).
The effect of antipsychotics on GABAA receptor expression. GABAA receptors containing β -1 sub-
unit were examined in the present study. The expression of GABAA β -1 receptors in the NAc was significantly 
affected by antipsychotic drug administration (F3, 20 = 4.926, p = 0.005). Both aripiprazole and haloperidol admin-
istration significantly increased GABAA β -1 receptor expression in the NAc, (aripiprazole, + 19.8%, p = 0.008; 
haloperidol, + 22.7%, p = 0.003) (Fig. 3C,D) but not in the PFC and CPu (Fig. 3A,B,D).
The effects of antipsychotics on NMDAR subunits expression. PFC. The expression of NR2A 
was significantly altered by antipsychotic drug administration in the PFC (F3, 20 = 4.976, p = 0.010), but not NR1 
(F3, 20 = 1.067, p = 0.137). Post-hoc tests revealed that NR2A levels were reduced by both aripiprazole (− 19.9%, 
p = 0.020) and haloperidol (− 27.9%, p = 0.002) (Fig. 5A,D).
CPu. The expression of NR1 and NR2A was not affected by drug administration in the CPu (NR1, F3, 20 = 0.082, 
p = 0.969; NR2A, F3, 20 = 0.909, p = 0.454) (Fig. 5B,D).
NAc. Both NR1 and NR2A expression was significantly changed by antipsychotic drug administration (NR1, 
F3, 20 = 4.653, p = 0.013; NR2A, F3, 20 = 6.923, p = 0.002). Post-hoc tests showed that aripiprazole increased the 
expression of both NR1 (+ 36.3%, p = 0.006) and NR2A (+ 41.9%, p = 0.001); haloperidol also elevated NR1 
expression (+ 27.4%, p = 0.033) in the NAc (Fig. 5C,D).
Figure 3. Effects of three antipsychotics on Dvl-3, β-catenin and GABAA (β-1) receptor expression.  
The effects of aripiprazole (ARI), bifeprunox (BIF) and haloperidol (HAL) on the expression of Dvl-3 and  
β -catenin were measured in the prefrontal cortex (A), caudate putamen (B) and nucleus accumbens (C). The 
representative bands of Western blot are shown in (D). Dvl-3 was quantified at 85 kDa; β -catenin was quantified 
at 92 kDa; GABAA (β -1) receptor was quantified at 54 kDa. The data were normalised by taking the average value 
of the control group as 100% and expressed as mean ± S.E.M. (* p ≤ 0.05, * * p < 0.01 vs the control).
www.nature.com/scientificreports/
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The effect of antipsychotics on CREB1 activity. The levels of CREB1 and p-CREB1 in the PFC 
and CPu were not altered by any of the three antipsychotic drug administration (Fig. 6A,B,D). In the NAc, 
antipsychotic drug administration had a significant effect on CREB1 (F3, 20 = 2.502, p = 0.045), p-CREB1 
(F3, 20 = 10.698, p < 0.001), as well as the ratio of p-CREB1/CREB1 (F3, 20 = 5.972, p = 0.002). Post-hoc tests showed 
that the expression of CREB1 was significantly elevated by administration of aripiprazole (+ 30.5%; p = 0.020). 
Additionally, the levels of p-CREB1 were significantly promoted by aripiprazole (+ 90.0%, p < 0.001) and halop-
eridol (+ 68.8%, p = 0.002) in the NAc (Fig. 6C,D); they also elevated the ratio of p-CREB1/CREB1 (aripiprazole, 
p = 0.019; haloperidol, p = 0.004) (Fig. 6C). Furthermore, the ratio of p-GSK3β /GSK3β was positively correlated 
with the ratio of p-CREB1/CREB1 (r = 0.572, p = 0.012) in the NAc (Fig. 4B).
The effect of antipsychotics on PKA activity. The levels of PKA-Cα and p-PKA-C were not changed in 
any brain regions after chronic antipsychotic administration in the present study (data not shown).
Figure 4. Correlations between the ratio of p-GSK3β/GSK3β and the ratio of the expression of β-catenin, 
and the ratio of p-CREB1/CREB1 in the NAc. The ratio of p-GSK3β /GSK3β was positively correlated with the 
expression of β -catenin (A), as well as the ratio of p-CREB1/CREB1 (B).
Figure 5. Effects of three antipsychotics on NMRA receptor subunits expression. The effects of aripiprazole 
(ARI), bifeprunox (BIF) and haloperidol (HAL) on the expression of NMDA receptor subunits NR1 and 
NR2A were measured in the prefrontal cortex (A), caudate putamen (B) and nucleus accumbens (C). The 
representative bands of Western blot are shown in (D). NR1 was quantified at 105 kDa; NR2A was quantified at 
165 kDa. The data were normalised by taking the average value of the control group as 100% and expressed as 
mean ± S.E.M. (* p ≤ 0.05, * * p < 0.01 vs the control).
www.nature.com/scientificreports/
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Discussion
The present study investigated the chronic effects of aripiprazole on Akt-GSK3β and Dvl-GSK3β -β -catenin sig-
nalling, PKA activity, GABAA (containing β -1) receptor expression, NMDAR subunits expression and CREB1 
activity in three brain regions, compared with haloperidol and bifeprunox. This is the first study to examine the 
chronic in vivo effects of aripiprazole on these cellular signalling pathways. The results have shown that all three 
antipsychotics had different effects on these signalling pathways, depending on the antipsychotic and the brain 
region.
Elevated Akt-GSK3β signalling in the pathophysiology of schizophrenia has been reported in a number of 
studies4,7,44–47. Various antipsychotics have shown increasing effects on the Akt-GSK3β signalling pathway in 
previous studies7–9,48,49. Previous acute and 1-week studies have also demonstrated that both aripiprazole and 
haloperidol increase the levels of p-GSK3β , but not p-Akt12,42. In the current study, chronic administration of all 
three drugs was able to increase the ratio of p-Akt/Akt and p-GSK3β /GSK3β in various brain regions, indicat-
ing reduced GSK3β activity in these brain areas; this is generally consistent with the findings of previous acute 
and short-term studies. It is worthy to note that aripiprazole is not only a D2R partial agonist, but also a biased 
antagonist at the β -arrestin250. It has been shown that inhibition of D2R mediated β -arrestin2-GSK3β signalling 
pathway is a common property that contributes to the therapeutic effects of various antipsychotics, including 
aripiprazole50–52, which has been confirmed in this chronic study. It should also be noted that antipsychotics 
affect Akt-GSK3β signalling in a time-dependent manner. Roh et al.53 found that the duration of p-Akt signalling 
induced by antipsychotics (about 1 hour) was much shorter than that of p-GSK3β . The time interval between the 
last administration and sacrifice in the previous12,42 and the present studies was longer than 1 hour. The levels of 
p-Akt were undetectable in the acute and short-term studies12,42, but were observed in this chronic study, which 
suggests that chronic administration of antipsychotic drugs might be able to have prolonged effects on Akt activ-
ity and thereby on Akt-GSK3β signalling.
Although aripiprazole, bifeprunox and haloperidol were able to influence GSK3β activity in the present study, 
their effects on GSK3β were not identical in each brain region. In the PFC, administration of aripiprazole and 
bifeprunox, but not haloperidol, was able to suppress the activity of GSK3β via the Akt-GSK3β signalling pathway. 
Aripiprazole and bifeprunox also decreased total protein levels of both Akt and GSK3β in response to the chronic 
treatment of these two drugs. It has been suggested that inhibition of GSK3β contributes to the therapeutic effects 
of antipsychotics48 and the functional impairment in the PFC is related to the negative symptoms and cognitive 
deficits of schizophrenia54. Our results suggested that the therapeutic effects of aripiprazole on the negative symp-
toms and cognitive deficits of schizophrenia might be attributed to its inhibiting effects on GSK3β activity in the 
PFC. Furthermore, bifeprunox was able to improve the negative symptoms of schizophrenia in clinical trials55 
and it inhibited the activity of GSK3β in the present study, which further confirms that suppression of GSK3β 
activity is very likely to be associated with the effects of antipsychotics on the negative and cognitive symptoms 
Figure 6. Effects of three antipsychotics on CREB1 activity. The effects of aripiprazole (ARI), bifeprunox 
(BIF) and haloperidol (HAL) on CREB1 activity were measured in the prefrontal cortex (A), caudate putamen 
(B) and nucleus accumbens (C). The representative bands of Western blot are shown in (D). CREB1 was 
quantified at 40 kDa; p-CREB1 was quantified at 37 kDa. The data were normalised by taking the average value 
of the control group as 100% and expressed as mean ± S.E.M. (* p ≤ 0.05, * * p < 0.01 vs the control).
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of schizophrenia. In contrast, haloperidol did not display any significant effects on GSK3β in the PFC in the 
present study and a previous acute study42, which may explain why haloperidol does not have therapeutic effects 
on the negative symptoms and cognitive deficits of schizophrenia. It should be noted that the present study did 
not found any changes of β -catenin, CREB1 and GABAA receptor in the PFC. Therefore, whether antipsychotics 
control the negative symptoms and cognitive deficits of schizophrenia via the enhancement of Akt-GSK3β signal-
ling requires further validations. In the NAc, administration of all three drugs increased the phosphorylation of 
both Akt and GSK3β in the present study. Since abnormal function of the NAc is linked to the positive symptoms 
of schizophrenia56, our results indicated that the suppression of GSK3β functions via the Akt-GSK3β signalling 
pathway in the NAc is very likely to be involved in the therapeutic effects of antipsychotics (probably on the 
positive symptoms of schizophrenia) (Fig. 7A). In the CPu, chronic treatment with these antipsychotics had very 
limited effects on the Akt-GSK3β signalling pathway, which suggests that GSK3β activity in the CPu may not be 
involved in the long-term clinical effects of antipsychotics. Yager et al.57 have reviewed that the NAc and CPu 
are heterogeneous structures with different neural inputs and outputs connected with various brain regions. For 
example, the NAc receives dopaminergic inputs from the ventral tegmental area, while sending outputs to limbic 
areas and the PFC; the CPu receives dopaminergic inputs from the substantia nigra pars, while sending projec-
tions to neocortical areas57. Therefore, chronic antipsychotic treatment might have different in the NAc and CPu. 
However, the brain-regional differences in the effects of antipsychotics require further clarification.
Previously, various classes of antipsychotics (e.g. aripiprazole, haloperidol, clozapine and risperidone) have 
been found to be able to increase the expression of Dvl-3 and/or β -catenin in various brain regions of animals, 
including the frontal cortex and striatum, indicating enhanced activity of β -catenin in these brain areas8–11. The 
current data has demonstrated that Dvl-3 and β -catenin expression was significantly increased by administration 
of both aripiprazole and haloperidol in the NAc only. These results are partly consistent with those of previous 
studies. Since dysfunction of the NAc is associated with the positive symptoms of schizophrenia and the main 
target of antipsychotics56 as mentioned above, the present study suggests that regulation of β -catenin via GSK3β 
might be a common mechanism by which antipsychotics exert their effects, even if they have different pharmaco-
logical profiles (Fig. 7A). It is further suggested that the increased expression of β -catenin in the NAc is very likely 
to be a route through which antipsychotics exert their therapeutic effects, especially on the positive symptoms of 
schizophrenia.
It has been reported that chronic haloperidol administration increased the binding of GABAA receptors in the 
NAc; and both haloperidol and clozapine administration also increased GABAA receptor binding in the limbic 
cortex25. A recent short-term study has demonstrated that both aripiprazole and haloperidol increased GABAA 
(containing β -1) receptor expression in the NAc (although the increasing effect of haloperidol did not reach 
significance)17, which is validated by the present study. In this study, we found that chronic administration of 
Figure 7. A proposed schematic diagram illustrating the chronic effects of aripiprazole and haloperidol on 
cellular signalling in the nucleus accumbens. D2 receptor antagonists (e.g. haloperidol) and D2 receptor partial 
agonists (e.g. aripiprazole) bind with the dopamine D2-like receptor, resulting in the phosphorylation of Akt 
and the subsequent phosphorylation of GSK3β probably via biasedly antagonising D2R-mediated β -arrestin2, 
together with the activation of the Dvl-GSK3β -β -catenin pathway (A), which might contribute to the therapeutic 
effect of antipsychotics. On the other hand, antagonism of the D2-like receptors by aripiprazole and haloperidol 
leads to increased expression of GABAA (β -1) receptors probably via the activation of PKA activity (indicated as 
a dashed arrow) (B), and enhanced CREB1 activity via the activation of GSK3β activity and PKA activity  
(C), both of which might also be involved in the therapeutic actions of antipsychotics.
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aripiprazole and haloperidol were able to significantly increase GABAA (containing β -1) receptor expression in 
the NAc, but no effects were shown in the other two brain regions. Since dysfunction of the NAc is related to the 
positive symptoms of schizophrenia56 as mentioned above, our findings together with other studies, suggest that 
increased GABAA receptor expression and probably enhanced GABAA signalling transmission in the NAc is very 
likely to be involved in the therapeutic effects of antipsychotics (possibly on the positive symptoms of schizophre-
nia) (Fig. 7B). It is worth noting that the GABAA receptor is regulated by D2-like receptor downstream PKA sig-
nalling58,59. A 1-week study has revealed that PKA phosphorylation levels in the NAc, paralleling the expression 
of GABAA receptors, was increased by aripiprazole and haloperidol17. In this chronic study, the effects of aripipra-
zole and haloperidol in increasing GABAA receptor expression persisted, whereas the changes in PKA activity 
were undetectable. The reason is unknown. It is possible that the up-regulated expression of GABAA receptors by 
short-term antipsychotic drug administration (through PKA) is an adaptive and prolonged change; even if there 
was no further alteration in PKA activity after chronic administration (probably due to adaptive changes in D2Rs), 
the increased GABAA receptor expression could be maintained.
A variety of studies has indicated dysfunction of NMDARs in schizophrenia5. In the current study, both arip-
iprazole and haloperidol administration was able to increase the expression of NMDAR subunits in the NAc, but 
reduce it in the PFC. Specifically, aripiprazole increased the expression of both NR1 and NR2A in the NAc, while 
haloperidol increased NR1 expression; in the PFC, both aripiprazole and haloperidol decreased NR2A levels. 
Previously, Segnitz et al.41 have reported that NR2A mRNA levels were decreased in the PFC by aripiprazole 
treatment for 4 months, but not changed in the CPu; Schmitt et al.40 have also found reduced NR2A mRNA in the 
PFC induced by both haloperidol and clozapine treatment. Furthermore, it was found that 4-week administration 
with haloperidol and D2-like receptor antagonist – raclopride increased the levels of both protein and mRNA 
of NR1 in the striatum39. Additionally, [3H]-MK-801 binding in the NAc was increased by haloperidol40. These 
previous findings are consistent with those of this study that both typical and atypical antipsychotics can increase 
NMDARs expression in the striatum (particularly in the NAc, but not in CPu), and reduce NR2A expression in 
the PFC. It is worth noting that antipsychotics have very low affinity with NMDARs. Therefore, it is necessary to 
further reveal through which pathway(s) antipsychotics regulate NMDARs.
Previously, haloperidol was able to increase phosphorylation levels of CREB1 in the striatum and hippocam-
pal neuron culture28–30. In addition, amisulpride, clozapine and olanzapine were also able to induce CREB1 phos-
phorylation in in vitro studies31–33. A 1-week in vivo study has shown that a 1-week administration of aripiprazole 
increased the expression of CREB1 in the NAc17. In the present study, chronic administration of aripiprazole 
increased CREB1 expression in the NAc; and both aripiprazole and haloperidol enhanced CREB1 activity via 
increasing the ratio of p-CREB1/CREB1. This confirmed that CREB1 is involved in the actions of antipsychotics. 
Moreover, extensive communication occurs between CREB1 and PKA, and the Akt-GSK3β pathway60. In the 
present study, we did not observe any change in PKA activity, nor in the correlation between PKA and CREB1 
activity in the NAc (indicated as a dashed arrow in Fig. 7C). However, GSK3β activity is positively correlated with 
CREB1 activity. A previous study has indicated that CREB1 activity was increased by inhibition of GSK3β in cul-
tured rat cerebral cortical neurons33. Amisulpride also induced the phosphorylation of CREB1 via the Akt-GSK3β 
pathway in SH-SY5Y cells32. Since patients with novel variants in the CREB1 gene experienced the positive symp-
toms of schizophrenia27, our data suggests that activation of CREB1 via the Akt-GSK3β pathway in the NAc is 
very likely to be associated with the therapeutic effects of aripiprazole and haloperidol on the positive symptoms 
of schizophrenia (Fig. 7C). It is worth noting that Mavrikaki et al.34 suggested that phosphorylation of CREB1 was 
increased by 3-week injection of aripiprazole in the PFC and striatum of rats, probably through NMDA recep-
tors. The regulation of CREB1 via NMDARs has also been confirmed by other studies61,62. The present study has 
shown both aripiprazole and haloperidol were able to increase CREB1 phosphorylation and NMDAR expression 
in the NAc, simultaneously. Whether the increased expression of NMDARs (partly) contributes to the enhanced 
phosphorylation of CREB1 in the NAc requires further validations. Lastly, phosphorylation of histone H3S10, an 
epigenetic modification, has been reported to be significantly increased in schizophrenia patients63. Since histone 
H3 phosphorylation could be regulated by G protein-coupled receptor and NMDAR signalling64, it is important 
to further investigate how the modulations of antipsychotics on these signalling pathways contribute to their 
therapeutic effects.
In summary, the present study has demonstrated that chronic administration of aripiprazole had dif-
ferent effects on the Akt-GSK3β , Dvl-GSK3β -β -catenin, GABAA receptor and CREB1 activity in a brain 
region-dependent manner. Compared to the effects of haloperidol only in the NAc and bifeprunox mainly in 
the PFC, aripiprazole affected these cellular signalling pathways in both the PFC and NAc, which may explain its 
unique clinical effects. It is also worth noting that the present and previous studies mentioned above examined 
the effects of antipsychotic drugs in healthy animals. It is necessary to investigate the effects of antipsychotics in 
the animal models for schizophrenia and other mental disorders in future studies.
Methods
Animals and drug administration. Male Sprague-Dawley rats (aged 8 weeks) were obtained from the 
Animal Resource Centre (Perth, Australia). After arrival, all rats were housed in individual cages under envi-
ronmentally controlled conditions (temperature 22 °C, light cycle from 07:00AM to 07:00PM), with ad libitum 
access to water and standard laboratory chow diet. All experimental procedures were approved by the Animal 
Ethics Committee (Application #: AE11/02), University of Wollongong, and complied with the Australian Code 
of Practice for the Care and Use of Animals for Scientific Purposes (2004). All efforts were made to minimise 
animal distress and prevent suffering.
Before drug administration commenced, the rats were trained for self-administration of the sweet cookie 
dough pellets for a week. Then the rats were randomly assigned into one of the following drug treatment groups 
(n = 6/group): aripiprazole (0.75 mg/kg; Otsuka, Japan), bifeprunox (0.8 mg/kg; Otava, Ukraine), haloperidol 
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(0.1 mg/kg; Sigma, Australia), or vehicle. Drug powder mixed with the cookie dough pellets was delivered orally 
3 times per day at 07:00AM, 03:00PM and 11:00PM for 10 weeks. This drug administration method aims to 
mirror the human scenario of oral administration and has been well-established in our laboratory17,65,66. These 
dosages were transferred from the recommended dosages in humans based on body surface area, according to 
the FDA guidelines for clinical trials67,68. A 0.75 mg/kg aripiprazole, 0.8 mg/kg bifeprunox and 0.1 mg/kg halo-
peridol dosage in rats is equivalent to ~7.5 mg, ~8 mg and ~1 mg in humans (60 kg body weight), respectively, 
all of which are within the recommended clinical dosages55,69,70. Moreover, the dosages used in this study have 
been shown to be physiologically and behaviourally effective in rodents, without inducing EPS side-effects71–74. 
After 10-week administration, all animals were euthanised in a CO2-filled chamber. Brains were immediately 
removed and frozen in liquid nitrogen. All animals were sacrificed between 09:00AM and 11:00AM to minimise 
circadian-induced variation of protein expression.
Brain dissection. The discrete brain regions were collected using a brain microdissection puncture tech-
nique, which has been well-established17,42. Specifically, based on the brain atlas75, three sections through the fore-
brain (Bregma 3.30 to 4.20 mm) were dissected for the PFC; and three sections through the striatum (Bregma 1.00 
to 2.20 mm) were dissected for the NAc and CPu, respectively. Dissected tissue was kept at − 80 °C for future use.
Western blots. Frozen brain samples were homogenised in homogenising buffer (9.8 ml NP-40 cell lysis 
buffer (Invitrogen, #FNN0021) mixed with 100 μ l Protease Inhibitor Cocktail (Sigma-Aldrich, #P8340), 100 μ l 
β -Glycerophosphate (Sigma-Aldrich, #G9422) and 33.3 μ l phenylmethylsulfonyl fluoride (Sigma-Aldrich, 
#P7626)). Protein concentration of each sample was measured by the DC Protein Assay (Bio-Rad, #500-0111). 
Each sample containing 10 μ g of protein was denatured at 95 °C, and loaded into 4–20% CriterionTM TGXTM 
Precast Gels (Bio-rad, #5671095). The gels were run vertically in CriterionTM Vertical Electrophoresis Cell 
(Bio-rad, #1656001) until the proteins separated, followed by the electrophoretical transfer of the proteins 
to a polyvinylidene difluoride membrane in CriterionTM Blotter (Bio-rad, #1704071). All membranes were 
then blocked by 5% skim milk powder and incubated in primary antibodies. Amersham Hyperfilm ECL (GE 
Healthcare, #28-9068-36) and Luminata Classico Western HRP substrate (Millipore, #WBLUC0500) were used 
to visualise the immunoreactive bands. All Western blot experiments were performed in duplicate to ensure 
consistency.
The antibodies used in the present study to examine PKA activity were anti-PKA-Cα (1:1000; Santa Cruz, 
#SC-903) and anti-phosphor-PKA-C (Thr197) (1:1000; Cell Signalling, #5661). The antibodies used to exam-
ine the GSK3β -involved pathways were anti-Akt (1:2000; Cell Signalling, #4691), anti-phosphor-Akt (Thr308) 
(1:1000; Cell Signalling, #13038), anti-GSK3β (1:2000; Cell Signalling, #5676), anti-phospho-GSK3β (Ser9) 
(1:1000; Cell Signalling, #9322), anti-Dvl-3 (1:1000; Santa Cruz Biotechnology, #SC-8027), anti-β -catenin 
(1:1000; Santa Cruz Biotechnology, #SC-7963). The antibodies used to detect subunits of GABAA receptors were: 
anti-GABAA β -1 (1:1000; Abcam, #ab154822), anti-GABAA β -2 (1:1000; Abcam, #ab156000), and anti-GABAA 
β -3 (1:1000; Abcam, #ab98968). The antibodies used to examine NMDAR were anti-NMDAR1 (1:2000, Abcam, 
#ab109182) and anti-NMDAR2A (1:500, Abcam, #ab124913). In addition, anti-CREB1 (1:2000, Abcam, 
#ab32515) and anti-phospho-CREB11 (1:2000, Abcam, #ab32096) were used to measure the activity of CREB1. 
Mouse anti-actin primary polyclonal antibody (1:10000; Millipore, #MAB1501) was used to determine the actin 
levels. The secondary antibodies were HRP-conjugated anti-rabbit IgG antibody (1:3000; Cell Signalling, #7074) 
and HRP-conjugated anti-mouse IgG antibody (1:3000; Cell Signalling, #7076). Examples of full pictures of the 
blots for each antibody are shown in the Supplementary file.
Statistics. All data were analysed using SPSS Statistics V22.0 program. The immunoreactive signals 
were quantified using Bio-Rad Quantity One software. The data of each targeted protein were then cor-
rected based on their corresponding actin levels. Data normal distribution was tested using histograms and a 
Kolmogorov-Smirnov Z test. For statistical evaluation, one-way analysis of variance (ANOVA) was performed 
if the data was normally distributed. The post-hoc Dunnett t test was used to compare each drug treatment 
group with the control group. The results were normalised by taking the value of the control group as 100%. 
Pearson’s correlation test was used to analyse the relationships among the measurements. Statistical significance 
was accepted when p ≤ 0.05.
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